Cary J Claiborne
CIK 1370930 · Chief Executive Officer · last filed 2026-04-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$124.5K
Companies
6
Total Filings
43
Lifetime Open-Market Net
-$706.4K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ADIL | Chief Executive Officer | 40,417 | $3.08 | $124.5K | $0 | 4 | 2026-04-09 |
| ADIAL PHARMACEUTICALS, INC. (ADILW) Delisted | Chief Executive Officer | 1,520,000 | $0.00 | $1.4K | $0 | 6 | 2023-05-25 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Chief Financial Officer | 45,764 | — | — | -$734.6K | 18 | 2014-12-17 |
| New Generation Biofuels Holdings, Inc (NGBF) Delisted | CEO, CFO and President | 283,179 | — | — | $28.2K | 9 | 2009-12-29 |
| New Generation Biofuels Holdings, Inc (GNB) Delisted | Chief Financial Officer | 10,236 | — | — | $0 | 1 | 2008-06-06 |
| OSIRIS THERAPEUTICS, INC. (OSIR) Delisted | Chief Financial Officer | 75,000 | — | — | $0 | 3 | 2007-11-23 |
Recent Filings · Page 3 of 5
43 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-07-02 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +280 | $1.8K | EDGAR |
| 2013-05-29 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Exer (X) | −10,300 | -$92.7K | EDGAR |
| 2013-05-22 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Sell (S) | −4,640 | -$44.2K | EDGAR |
| 2013-04-05 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +242 | $1.5K | EDGAR |
| 2013-01-04 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +376 | $1.8K | EDGAR |
| 2012-10-02 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +313 | $1.5K | EDGAR |
| 2012-07-20 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +263 | $1.8K | EDGAR |
| 2012-04-06 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +211 | $1.5K | EDGAR |
| 2011-10-27 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-12-29 | New Generation Biofuels Holdings, Inc (NGBF) Delisted | Buy (P) | +20,000 | $14.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.